Best GLP-1 After Failing Zepbound: Your Next Step, Matched to What Went Wrong

No study has established one best GLP-1 after failing Zepbound. Wegovy is a different drug worth discussing when tirzepatide has not helped enough, but it is not a proven rescue. First, review your dose, time on treatment and results. Side effects, sleep apnea and cost can point to a different next step.¹²

Disclosure: Some links on this page are paid affiliate links, marked "(paid link)." If you start care through one, we may earn a commission at no extra cost to you. Every table and checklist on this page works without choosing a provider through us. How we make money

But before you switch anything, check one date: when you started the dose you and your prescriber chose for long-term treatment.

Zepbound's fastest labeled climb reaches 15 mg after 20 weeks. Adding 12 to 16 weeks at that dose gives a review window about 7 to 8 months after your first shot. That's a planning example, not a rule to keep taking a drug that makes you sick or gives too little benefit. You do not have to reach 15 mg.³⁴

Side effects, sleep apnea, insurance and cost can all change the answer. Each one gets its own section below.

If Zepbound let you down, you're not broken. In Zepbound's big trial, the estimated share losing less than 5% at 72 weeks was about 1 in 11 in the 15 mg group. That figure includes people who stopped treatment; it is not a test of why an individual did not respond. It happens. It doesn't mean you're out of options.³

Check your Zepbound treatment history → Free. No email. Uses your own shot dates and weights.

Is this page for you?

Yes, if:

• You have taken Zepbound at a dose you can handle and want to know whether the weight loss is enough to keep going.
• You lost weight, then stalled before your goal.
• Side effects, cost or your insurance pushed you off Zepbound, and you want to know what comes next.

No, go here instead if:

• You take Zepbound for sleep apnea. It is approved for moderate to severe obstructive sleep apnea in adults with obesity. Talk to your sleep doctor before switching.³ → Best GLP-1 for sleep apnea
• You just want a list of Zepbound alternatives, for any reason. → Best Zepbound alternatives
• You or a family member had medullary thyroid cancer, or you have MEN 2. Both drugs are ruled out by their labels. A family history of MEN 2 also needs a clinician's review.³⁵ → GLP-1 boxed warnings
• You feel sick right now. Severe belly pain that won't stop, or vomiting so bad you can't keep fluids down, needs prompt medical care. Swelling of the face or throat or trouble breathing needs emergency care—call 911. This page can wait.³

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

On this page: Find your situation · Did it really fail? · Is Wegovy next? · Timeline to Wegovy HD · Anything stronger? · Pills · Side effects · Stalled · Cost · Insurance · If nothing works · What to bring · Who can help · Special cases · FAQ

Which next step fits what happened on Zepbound?

Zepbound "failing" can mean five different things: too little weight loss at a full dose, a stall after real weight loss, side effects, a cost or coverage problem, or judging it too early. Each problem has a different best next step. Swapping drugs only fixes some of them.

Find the row that sounds like you. Then jump to that section.

Use the Zepbound Treatment Check

Use your own shot dates and weights to prepare a better treatment review.

1. Find your percent lost. Subtract today's weight from your weight when you started Zepbound. Divide by that starting weight, then multiply by 100. Example: 240 lb to 230 lb is 4.2% lost.
2. Check time at your current dose. Write down when you started it and any gaps. The review calendar below gives planning examples, not a pass-or-fail diagnosis.
3. Name the real problem. Too little loss, a stall, side effects, cost, coverage or needles? Use the matching row above.
4. Take the record to your prescriber. Copy or print the Zepbound Trial Record, including the five questions at the end.

Get my Zepbound Trial Record →

Free. No email. This is a worksheet, not a medical test. It does not pick a drug or dose.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, your medication needs, whether you prefer an injection or oral medication, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to explore care options before you choose. A clinician must decide whether changing treatment is right for you.

Did Zepbound really fail, or is it too early to tell?

Maybe not yet. The Obesity Medicine Association suggests considering another medicine when weight loss stays below 5% after 12 to 16 weeks at the highest tolerated dose. That is a reason for a treatment review—not an FDA rule that you must wait that long or reach 15 mg.⁴³

The 5% review point comes from the Obesity Medicine Association. Your prescriber should also consider side effects, treatment gaps, health benefits and the goals you agreed on.⁴

Here's the catch. Zepbound climbs slowly on purpose, to spare your stomach. The label starts everyone at 2.5 mg for 4 weeks. Then the dose goes up 2.5 mg at a time, at least 4 weeks apart.³

So if you judged Zepbound at the 3-month mark, you may still have been moving through doses. But 5 mg is a real maintenance dose, not just a warm-up.³

Your Zepbound treatment-review calendar

We built this from the label's fastest dose steps plus the 12-to-16-week review point. Any delay between steps pushes these example dates later. Count elapsed weeks from your first shot; 20 weeks after that shot is the start of treatment week 21.³⁴

Our math: the week you reach your dose, plus 12 to 16 weeks. Months = weeks × 7 ÷ 30.44.

You don't have to reach 15 mg. Zepbound's label lists 5, 10 and 15 mg as long-term doses. It says to pick one based on how well it works and how well you handle it. The 2.5 mg dose is only for starting. The calendar gives you a date to discuss, not permission to ignore side effects or keep going without review.³

Where did you land in Zepbound's big trial?

SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. We turned its published results into bands, so you can see where your own number falls.³

These are estimated percentages, not raw counts. The analysis includes people regardless of whether they stopped treatment, and it estimates missing week-72 weights. Our math, from the published cutoffs: at 15 mg, 90.9% lost at least 5%, so 100 − 90.9 = 9.1% lost less. The other bands subtract each higher cutoff from the next lower one.³

Two things to know about this table:

• Do not read this as your personal odds. Stopping treatment, missing data and the study's analysis method affect these estimates. They do not tell us why each person lost less than 5%.
• Diabetes changes the math. In SURMOUNT-2, adults with type 2 diabetes averaged 14.7% at 15 mg after 72 weeks.³

Trial results come from 72 weeks with regular diet and activity coaching. Your own treatment history may be very different. Want to see your percent as pounds? → Percent vs pounds lost

Slow starters often catch up

A 2025 follow-up study looked at people in SURMOUNT-1 who had lost less than 5% by week 12. That was 278 people, or 18% of the group studied.¹¹

Most of them caught up. 70% reached 5% by week 24, and 90% (250 of 278) got there by week 72. Among the late responders who reached 5%, it took about 25 weeks on average.¹¹

That is why a slow start deserves a review of the actual dose history, not a rushed label of failure.

One honest limit: that study only included people who took at least 75% of their doses and had weights recorded at weeks 12, 24 and 72. It doesn't mean you have a 90% chance. It means a slow start isn't a verdict.¹¹

Six things that look like failure but may not be

1. You stopped climbing for a reason other than side effects. 5 mg is a real long-term dose, but it averaged 15.0% in the trial versus 20.9% at 15 mg. Ask whether a higher dose is right for you.
2. You are still early at the dose you and your prescriber chose. Check the review calendar and agree on a reassessment date.
3. You missed doses or had gaps. The label lets you take a missed shot within 4 days (96 hours). After that, skip it and take the next one on schedule. Keep at least 3 days (72 hours) between injections. Ask your prescriber how to restart after a longer gap.³ → Missed-dose guide
4. You have type 2 diabetes. Use results from a diabetes study when setting expectations; the Zepbound trial averages were lower in that population.³
5. You're at a plateau after real weight loss. That's a different problem. → Stalled after losing weight
6. What you took wasn't branded Zepbound. Bring the label or a photo to your prescriber. Compounded and "research" products are not FDA-approved Zepbound, and that history should not be treated as a verified trial of the branded product.¹²

Also ask your prescriber to look at your other medicines and any new health changes. Some can work against weight loss.

Low response or plateau? They're not the same problem

• Low response: little weight loss after enough time on a tolerated treatment plan. Under 5% after 12 to 16 weeks at the highest tolerated dose is one reason to discuss a different medicine.⁴ → Is Wegovy next?
• Plateau: you lost real weight, then it stopped. Review the weight you have kept off as well as the weight you still hope to lose.⁶ → What to do after a stall

Still climbing, and your prescriber just refills the script? A program with regular check-ins may help you review the dose and the plan—not simply push you to the highest dose. Ro advertises Zepbound cash prices that match LillyDirect. At the current $449 on-time refill price, moving from 10 mg to 15 mg does not raise the medicine charge. Ro's membership is extra.¹³¹⁴ See Zepbound care on Ro → (paid link)

Is Wegovy the best GLP-1 after failing Zepbound?

Wegovy is a reasonable GLP-1 to discuss after poor Zepbound results, but the evidence does not establish it as the best next drug for most nonresponders. It is a different medicine. Wegovy HD is an option for eligible adults who tolerate 2.4 mg for at least 4 weeks and need more weight reduction—not an automatic next step.¹⁵

Why a different drug can work when a "stronger" one didn't

Zepbound is tirzepatide. It copies two gut hormones, GIP and GLP-1, that tell your brain you're full. Wegovy is semaglutide. It copies just one, GLP-1.³⁵

In a head-to-head trial, tirzepatide produced more average weight loss than semaglutide at the doses tested. But bodies aren't averages. That study did not show which drug works best after an individual gets poor results from tirzepatide.²

Why put Wegovy on the discussion list?

Look at what's left once Zepbound is off the table:

• Mounjaro contains the same drug as Zepbound, tirzepatide. A different brand name is not a new way for the medicine to work.¹⁵
• Pills offer a different way to take treatment. They are not proven to rescue Zepbound nonresponse (more on that below).¹⁰
• Saxenda is a daily liraglutide shot. It is another GLP-1 option, but its availability does not establish that it will work after tirzepatide did not.⁴
• Wegovy HD averaged 18.8% weight loss at 72 weeks in STEP UP, compared with 15.5% for Wegovy 2.4 mg in the same trial. That was not a study of Zepbound nonresponders.⁵

That's why Wegovy belongs in the discussion. Your treatment history decides whether it belongs in your plan.

What the evidence actually answers

Most comparisons focus on whether Zepbound beat Wegovy. That's not your question. Here's what the research shows about switching, and what it doesn't.

The number we double-checked

That case report's abstract reports 20% weight loss on semaglutide. We opened the report's table to check the math.

He started at 115 kg (about 254 lb). After tirzepatide, he weighed 109.5 kg. After semaglutide, he weighed 92 kg.

• From his very first weight: 115 → 92 = 20% lost overall.
• From the day he switched: 109.5 → 92 = about 16% lost on semaglutide.

Still a big result. But if you read "20% after switching" somewhere, that's not quite what happened. And one person's result can't predict yours.¹

What to expect if you switch

• Agree on a starting dose and handoff date. The labeled new-start schedule begins at 0.25 mg weekly. There is no approved Zepbound-to-Wegovy dose conversion; your prescriber must plan the switch.⁵
• Set the review date before you start. Use your response, side effects and agreed goals to judge the plan. The 12-to-16-week guidance is a discussion point, not a reason to ignore a problem.⁴
• Plan your Plan C in the same visit. If one strong GLP-1 barely worked, ask now what you'd try if the next one doesn't. → If no GLP-1 works

Three more reasons Wegovy may fit you better

• You have heart disease. Wegovy is approved to lower the risk of heart attack, stroke and heart death in adults with heart disease and overweight or obesity. In SELECT, the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke fell by 20% relative to placebo. That does not mean each event fell by 20%.⁵ Zepbound doesn't have that approval.
• You have MASH, a fatty-liver disease with scarring. Wegovy injection is approved for adults with noncirrhotic MASH and moderate to advanced fibrosis, called stages F2–F3. This is an accelerated approval. The labeled MASH maintenance dose is 2.4 mg, not HD 7.2 mg.⁵
• Your plan prefers Wegovy. Some big drug lists do. → Insurance

Who shouldn't switch to Wegovy yet

• You're still moving through doses and have not reviewed whether a switch would solve the actual problem.
• You take Zepbound for sleep apnea and your sleep doctor hasn't weighed in.
• You're planning a pregnancy soon. Wegovy's label says to stop at least 2 months before trying.
• You or a family member had medullary thyroid cancer, or you have MEN 2.³⁵

Our read: After a well-documented trial of Zepbound with too little benefit, ask about Wegovy and a Plan C at the same visit. HD may be an option later if it fits the label and your needs. And don't let anyone promise you a sure thing. Nobody has a reliable success rate for this switch yet.¹¹⁶

One honest thing about Ro before you click. Ro's advertised weight-program menu focuses on brand-name GLP-1 medicines. It does not list older non-GLP-1 pills like Qsymia as a treatment option. If you've already decided GLP-1s aren't for you, an obesity medicine doctor is the better fit.¹³ → If no GLP-1 works

Ro advertises Wegovy at the manufacturer's cash prices: $199 for up to two eligible 0.25 mg or 0.5 mg fills through December 31, 2026, then $349 for doses through 2.4 mg. The starter offer is for people new to the Wegovy Savings Offer or NovoCare Pharmacy—not simply anyone switching drugs. Ro also offers insurance-paperwork support; a prescription or coverage approval is not guaranteed.¹³⁸

Reached your top Zepbound dose and still under 5%? See if Wegovy is right for you on Ro → (paid link) Get started for $39, then as low as $74/month with annual plan paid upfront. The $39 is refunded if you're not eligible for GLP-1s. Wegovy is billed separately.¹³

How long does it take to switch from Zepbound to Wegovy HD?

On Wegovy's standard new-start schedule, HD is first possible after about 5 months: 16 weeks moving through the lower doses, then at least 4 weeks tolerating 2.4 mg. A switch can take longer. There is no approved dose conversion between Zepbound and Wegovy, and they should not be taken together.⁵³

Here's the standard new-start path, with current NovoCare cash prices for each 28-day fill. This is not a personal dosing plan.⁵⁸

The $199 offer is limited to up to two eligible starter-strength fills by December 31, 2026. Price does not determine the right dose.

A few rules that keep you safe:

• Never overlap. Both labels say not to take them together. Your prescriber picks the handoff day.
• No official conversion. Do not use your old Zepbound dose to pick a Wegovy dose. Your prescriber needs your last injection date, dose, symptoms and any treatment gaps.⁵
• Have a plan for symptoms and hunger. Discuss what to do if either changes during the switch. Side effects can return during dose increases.⁵
• Watch for altered skin feelings at HD. In the label's pooled 7.2 mg trials, unusual sensations such as tingling or skin sensitivity were reported in 22% on 7.2 mg versus 6% on 2.4 mg.⁵ → Wegovy HD side effects

Step-by-step switching details: → How to switch from Zepbound to Wegovy

Is anything stronger than Zepbound?

There is no approved, proven 'next level up' specifically for people who got too little benefit from Zepbound. Fifteen mg is its highest approved weekly dose. Wegovy HD has not been tested head to head against it; retatrutide and CagriSema remain investigational as of this review.³⁵¹⁷¹⁸

We get why people ask. If Zepbound didn't work, you want the next level up. Here's the honest status as of September 2026.

Mounjaro is the same drug

Mounjaro and Zepbound both contain tirzepatide. Mounjaro carries the diabetes label; Zepbound carries the weight label. In August 2026, the FDA also approved Mounjaro to lower heart-attack and stroke risk in adults with type 2 diabetes at high heart risk. That's a real change, but it's still the same medicine.¹⁵ → Why Mounjaro isn't approved for weight loss

Should you wait for retatrutide?

Do not leave a treatment gap just to wait for a company timetable. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. Review and any approval would come later. Ask your clinician about available care now or legitimate clinical-trial participation.¹⁷

Skip the "research peptide" sites. The FDA says retatrutide is not an approved drug and cannot be used in compounding under federal law. An online "research" offer is not an FDA-approved prescription product. Legitimate clinical trials are different from buying a peptide online.¹²

More: Retatrutide availability · Retatrutide results · CagriSema vs Zepbound · Obesity drug pipeline

Would a GLP-1 pill work better after Zepbound?

A pill is not proven to work better after Zepbound gives too little weight loss. Pills make more sense when taking shots is the problem or when you want to discuss keeping off weight already lost. In a trial of prior Zepbound responders, orforglipron helped retain more of that loss than placebo.¹⁰

A pill fixes a needle problem. It does not come with proof that it fixes a response problem.

Ro says the 2.5 mg and 5.5 mg Foundayo offers require signup by December 31, 2026. The 14.5 mg and 17.2 mg prices require the manufacturer offer. These are medicine prices, not the total cost of care.¹³

The pill study built for Zepbound users

ATTAIN-MAINTAIN enrolled people after weight loss on injectable semaglutide or tirzepatide. In the prior tirzepatide group that had reached a plateau, participants switched to orforglipron or placebo for 52 weeks.¹⁰

• Foundayo group: kept 74.7% of their weight loss on average.
• Placebo group: kept 49.2%.
• Some weight came back even with orforglipron. The 74.7% and 49.2% figures describe the share of earlier weight loss retained—not the share of people who maintained it.¹⁰

So this study does not establish Foundayo as a rescue for Zepbound nonresponse. It's a maintenance option for people Zepbound did help. → Is Foundayo worth it? · Wegovy pill vs injection

About compounded GLP-1s Compounded GLP-1s are mixed by pharmacies. They are not FDA-approved, and the FDA doesn't review them for safety, effectiveness or quality. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. A compounded product is not "generic Zepbound," and a compounded label does not establish a new or better treatment for nonresponse. That's why we don't list compounded providers on this page.¹²¹⁹ → Compounding rules in 2026 · Compounded vs name brand

What if Zepbound's side effects were the real problem?

Ask about the label's own options before switching for side effects. Zepbound's label allows consideration of a lower maintenance dose when a dose is not tolerated. Wegovy is not guaranteed to be gentler: in SURMOUNT-5, 5.6% stopped semaglutide because of stomach or bowel side effects versus 2.7% on tirzepatide. That group comparison does not predict your experience.³²

If nausea or constipation stopped you at 5 or 7.5 mg, tolerability is part of the treatment result—not a reason to dismiss what happened. Five mg is an approved long-term dose. You do not have to endure severe side effects to prove you tried hard enough.³

Ways to stay on Zepbound

• Ask about 5 mg. It's an approved long-term dose. It averaged 15.0% in SURMOUNT-1.³
• Ask about climbing more slowly. The label says to wait at least 4 weeks between steps. More time is allowed.³
• Get real help with symptoms. → GLP-1 nausea: what helps

If you need to leave Zepbound

Your prescriber may start a different drug at a low dose. That could be Wegovy, a pill, or a non-GLP-1 medicine. Just know that stomach side effects are common with these GLP-1 options, pills included.³⁵⁹ → GLP-1s with the fewest side effects

Get medical help right away if you have:

• Severe stomach pain that won't go away, with or without vomiting. It may spread to your back.
• Pain in your upper right belly, fever, or yellow skin or eyes.
• Vomiting or diarrhea so bad you can't keep fluids down.
• Swelling of the face, lips or throat, or trouble breathing. Call 911.³

What if you lost weight on Zepbound and then stalled?

A stall after meaningful weight loss is a plateau, not the same as never responding. A selected tirzepatide study group reached its defined plateau at median times of about 24 to 36 weeks, depending on starting BMI. That definition allowed small weight changes; it did not mean everyone stopped losing on a set date.⁶

Weight loss can slow even while treatment is helping you keep weight off. Review both the loss already achieved and the health goal still unmet.⁶

In a post hoc SURMOUNT-1 analysis of selected, adherent participants who lost at least 5%, the median time to the study's plateau definition was:

• About 24 to 26 weeks for people who started with overweight or a BMI under 35.
• About 36 weeks for people who started at a BMI of 35 or higher.

The researchers defined a plateau as less than 5% weight change over a 12-week period and later intervals. That is not a deadline for your body, and a median does not describe everyone.⁶

Three honest options after a stall

1. Hold and maintain. In SURMOUNT-MAINTAIN, selected responders first took tirzepatide 10 or 15 mg for 60 weeks, then were assigned a maintenance plan for 52 weeks. The 5 mg group regained about 5.6 kg (12 lb) in the reported efficacy analysis. A lower dose can help some people maintain, but it does not guarantee the same weight.²⁰ → GLP-1 maintenance doses
2. Maintain with a pill. Foundayo is the option studied for Zepbound users. → Pills
3. Still need more loss? Wegovy HD isn't proven to beat what you're already on. Talk to an obesity medicine doctor about add-on medicines or surgery. → If no GLP-1 works

Lifestyle side of a stall: → GLP-1 plateau reset. Thinking of stopping instead? → Weight regain after stopping Zepbound

How much does it cost to switch from Zepbound to Wegovy?

At current cash prices, 13 on-time Zepbound 10 or 15 mg fills cost $5,837 for 364 days. The Wegovy examples below cost $4,237 at 2.4 mg or $4,637 with HD—$1,600 or $1,200 less in medicine. Those savings require eligible starter offers and assume prices stay unchanged. Care fees are extra.¹⁴⁸

The medicine can cost less. The whole treatment plan may not.

We ran the numbers for 13 injection fills, covering 364 days, using prices checked September 22, 2026. This is a budget scenario, not a price guarantee or a reason to pick a dose. The HD example assumes the standard new-start schedule without delays.

Wegovy pill budget: Twelve 30-day fills cost $3,338 on the standard 1.5 mg → 4 mg → 9 mg → 25 mg schedule: $149 + $199 + 10 × $299. That covers 360 days, so it is not a same-duration annual comparison with the injection table.⁸

Prices checked September 22, 2026. LillyDirect lists these self-pay prices for eligible Zepbound vial or KwikPen purchases. A monthly supply is 28 days. Syringes or pen needles may cost extra. The $699 row uses the standard price without the Journey discount.¹⁴

The price traps nobody puts up front

• LillyDirect's 45-day rule. Zepbound 7.5 to 15 mg is $449 only if you refill within 45 days. Miss it and you pay $499 at 7.5 mg, or $699 at 10 or 15 mg.¹⁴
• The current $199 offer expires December 31, 2026. It covers up to two eligible 0.25 mg or 0.5 mg fills. Without that offer, the price currently shown for doses through 2.4 mg is $349; do not treat that as a guaranteed 2027 price.⁸
• "As low as $25" has a cap. The covered-commercial-insurance Wegovy offer provides up to $100 off per month, subject to its terms. A high copay can leave you paying more than $25.⁸
• Commercial copay cards are not for government-plan beneficiaries. Medicare, Medicaid and TRICARE restrictions apply. Manufacturer self-pay offers and the Medicare GLP-1 Bridge have separate rules; do not assume the same restriction or benefit applies to all three.⁸²¹

Don't forget the care fee

The prices above are medicine only.

• Ro: $39 for the first month, then $149 a month, or as low as $74 a month with an annual plan paid upfront.¹³
• Sesame: $99 month to month, or a $59 monthly equivalent on an annual plan. Some clinicians charge more.²²
• Using NovoCare or LillyDirect to fill an existing prescription: no telehealth membership is included in the medicine price. You still need a prescriber, and their care may have a separate cost.⁸¹⁴

One fee check before you switch: standard Wegovy at $349 plus Ro's $149 month-to-month care fee is $498 in a month when both charges fall due. That is not cheaper than $449 Zepbound medicine alone through an existing prescriber. Annual discounts change the comparison, and 28-day fills do not line up perfectly with calendar-month fees.¹³⁸¹⁴

Run your own numbers: → GLP-1 cost calculator · NovoCare prices · Zepbound self-pay prices · LillyDirect vs Ro

Will insurance cover Wegovy after Zepbound?

Your plan may cover Wegovy after Zepbound, but switching does not guarantee approval. Check whether your benefit includes weight-loss medicines, whether Wegovy is on the drug list, and whether a new prior authorization is required. Your Zepbound history helps explain the request; it does not override a plan exclusion.⁷

Some plans already prefer Wegovy

CVS Caremark, one of the biggest pharmacy benefit managers (the companies that run drug lists for insurers), made Wegovy its preferred weight-loss GLP-1 on July 1, 2025.⁷

CVS says that starting October 1, 2026, Zepbound will be an additional preferred option on standard formularies for plan sponsors that choose the option. That is not automatic coverage for every Caremark member, and prior authorization still applies.⁷ → Does CVS Caremark cover Zepbound?

Your plan will judge Wegovy too

Ask for the written rules for starting Wegovy and renewing it. A plan may require proof of benefit after treatment, and its rule may differ from the general clinical review point used above. Keep records from day one.

Also keep proof of your weight before you ever started Zepbound. Some plans look at your starting weight, not just today's.

Medicare, Medicaid and other government plans

• Medicare: The Medicare GLP-1 Bridge offers eligible Part D-enrolled beneficiaries a $50 monthly copay from July 1, 2026, through December 31, 2027. It is outside the regular Part D benefit. Covered products include Wegovy tablets and injections, Foundayo tablets, and Zepbound KwikPen—not Zepbound vials or single-dose pens. Changing drugs requires a new coverage review.²¹²³
• Bridge eligibility: You must be at least 18 and meet a BMI threshold when starting GLP-1 treatment: 35 or higher; 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a-or-worse chronic kidney disease; or 27 or higher with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. Your provider must certify participation in a diet-and-exercise program.²³
• When the Bridge is not the path: Medicare lists people already getting a GLP-1 through Part D, or with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, as ineligible for the Bridge. Your regular Part D plan may cover treatment instead.²³ → Medicare GLP-1 Bridge guide
• Medicaid: Coverage depends on your state. → What GLP-1 does Medicaid cover?
• Online programs: Ro says it does not coordinate coverage with government plans such as Medicare, Medicaid or TRICARE. It also says people with Medicaid cannot join Ro Body. Do not use its commercial-insurance service as a substitute for the Medicare Bridge process.²⁴

Your best evidence is your own record

Your Zepbound history is useful evidence. It shows what you tried, at what dose, for how long, and what happened. The plan may also ask for earlier weights, diagnoses, lifestyle-treatment records or its own form. A treatment record strengthens the explanation; it does not guarantee a prior authorization or appeal. → Copy your Zepbound Trial Record · Denial decoder · Free appeal letter template

Have insurance through work? Before you pay cash, run Ro's free GLP-1 coverage check → (paid link) It checks coverage for Ozempic, Wegovy and Zepbound pens. If you join, Ro's team handles the paperwork. Coverage and prescribing still depend on the plan and clinical review.²⁴

What if no GLP-1 works for you?

You still have real options. An obesity medicine doctor can look for things working against you, consider a non-GLP-1 medicine such as Qsymia or Contrave, or discuss weight-loss surgery. Major surgery guidelines recommend assessment at a BMI of 35 or higher, with additional criteria below that. Eligibility is not the same as insurance coverage.⁴²⁵

Here's the thing most pages won't say. If Zepbound barely worked and Wegovy barely works, you deserve more than another automatic GLP-1 refill. That's when a specialist earns their fee.

The medicine percentages come from different trials, not a comparison after Zepbound failure. The Qsymia figures shown are total changes in body weight, not differences from placebo.

A good specialist will also check the basics: other medicines that can cause weight gain, sleep, thyroid, and other health changes.

How to find one: look for a doctor who's board-certified in obesity medicine. Use the American Board of Obesity Medicine's physician directory. Bring your Zepbound Trial Record.

More: Contrave vs GLP-1 · GLP-1 vs bariatric surgery

Want your whole history on one page before that visit? Get my Zepbound Trial Record →

What should you bring to your next appointment?

Bring a record of your Zepbound doses and dates, your weights, your side effects and any missed shots. That record answers the first questions a new prescriber is likely to ask, and it keeps the visit focused on what to do next. Copy the template below into a note or print this section.

A 15-minute visit goes fast. This page makes it count.

My Zepbound Trial Record Weight before any weight-loss medicine: ______ lb or kg on ______ (date) Weight when I started Zepbound: ______ lb or kg First Zepbound shot: ______ (date) Each dose and the date I started it: 2.5 mg ______ · 5 mg ______ · 7.5 mg ______ · 10 mg ______ · 12.5 mg ______ · 15 mg ______ Highest dose I could handle: ______ mg, since ______ (date) Treatment-review date agreed with my prescriber: ______ Weight today: ______ lb or kg on ______ · Percent lost: ______% Lowest weight on Zepbound: ______ lb or kg on ______ Missed shots or gaps: ______ Side effects (what, when, at which dose): ______ Other medicines and health changes: ______ Insurance plan and any denial letters: ______ Why I'm asking about a change: too little loss / stalled / side effects / cost / coverage / needles Questions for my prescriber: 1. Have we had enough time and information to judge Zepbound at my dose? 2. What problem would switching solve for me? 3. If we try Wegovy, when will we judge it, and what's Plan C if it doesn't work? 4. Do my other conditions (heart, sleep apnea, diabetes, pregnancy plans) change the choice? 5. Who do I contact about side effects or refill problems?

The percent-lost math: (starting weight − today's weight) ÷ starting weight × 100. Use the same units for both. Example: (240 − 230) ÷ 240 × 100 = 4.2%.

Who should manage your next step?

Start with the clinician who manages your Zepbound, if they review your history and plan next steps with you. If they only refill the prescription, an online program with regular check-ins, or a clinician you choose, may fill that gap. A new platform doesn't make a drug work better; better follow-up is the point.

One Zepbound user on Reddit put it plainly: "He just sends in the meds."²⁸

If that's you, the issue may not be the drug alone. It may be that nobody is watching the calendar, the doses and the plan.

How we judge care options

The RX Index Score looks at five things, in this order: clinical legitimacy (is a licensed clinician really reviewing you?), care quality (does anyone follow up?), transparency (are prices and terms easy to find?), access (can you get it where you live and with your coverage?), and cost (what you'll really pay at the dose you'll take). We didn't give numeric scores on this page. We did not find published outcome data establishing which of these programs works best for people Zepbound failed. → Our methodology

What real Ro customers say

These are individual public reviews from Trustpilot. They describe care experiences, not weight-loss results, and your experience may differ.

"Meetings with the doctor online to discuss my concerns was great." — Diane, Trustpilot review of Ro, experience dated September 6, 2026.³⁰

"Easy to use. Expensive membership fee for little value." — David Socorro, Trustpilot review of Ro, experience dated September 9, 2026.³⁰

We show both on purpose. Ro's membership is worth it when you need what it adds: follow-up and insurance help. If your own doctor already does that well, you may not need it. → Our full Ro review

If you'd rather choose your own clinician

Sesame lets you browse clinicians and pick one for a video visit. That's useful if you want a second opinion or someone new to manage a switch to Wegovy. Just know its clinicians don't prescribe controlled weight-loss drugs like Qsymia or phentermine. For those, ask a clinician who can prescribe controlled medicines.

Want a fresh set of eyes on your Zepbound history? Compare Sesame clinicians and prices → (paid link) → Our Sesame review

Do sleep apnea, heart disease, diabetes or pregnancy change the answer?

Yes. Zepbound treats moderate to severe obstructive sleep apnea in adults with obesity, so talk to your sleep doctor before switching. Wegovy has cardiovascular and MASH indications for specific patients, but the approved formulation and dose matter. Diabetes medicines and pregnancy plans also change how a switch should be managed.³⁵

What you keep or lose by leaving Zepbound for Wegovy:

• Sleep apnea: Zepbound's long-term dose for sleep apnea is 10 or 15 mg. Don't trade it away without your sleep doctor. → Best GLP-1 for sleep apnea
• Heart disease: In SELECT, semaglutide reduced the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke by 20% relative to placebo—not each outcome by 20%.⁵ → Best GLP-1 for heart protection
• Type 2 diabetes: Mounjaro is the same drug as Zepbound. Tell the clinician who manages your diabetes before any switch, especially if you take insulin or a sulfonylurea, which raise the risk of low blood sugar. → Best GLP-1 for diabetes
• Pregnancy plans: Zepbound can make birth control pills work less well. Its label says to switch to a non-oral contraceptive or add a barrier method for 4 weeks after you start and for 4 weeks after each dose increase. Wegovy's label says to stop at least 2 months before a planned pregnancy. Weight-loss medicines should not be used during pregnancy; contact your prescriber promptly if you become pregnant.³⁵
• Thyroid history: A personal or family history of medullary thyroid cancer, or MEN 2 in you, rules out both Zepbound and Wegovy. Tell your clinician about a family history of MEN 2 too.³⁵ → GLP-1 boxed warnings

How did we check this page?

We checked drug labels, original research, company trial announcements, program rules and published price pages, and we dated the prices. Our next-step framework is editorial judgment built on those facts. Published provider terms were checked; actual consultations, service quality and your eligibility were not tested.

Why this page exists: When Zepbound doesn't work, it can feel like the end of the road. It usually isn't. We wanted one place with the calendar, the evidence, the real costs and the next steps, so your next visit is shorter and clearer.

What we actually verified

We did not sign up for any program or test its response times. No clinician reviewed this page, so we don't claim one did. Found an error? Tell us.

Verification log: September 22, 2026: labels, cited research, program rules and public prices checked.

Frequently asked questions

What is the best GLP-1 after failing Zepbound?

No study establishes one best choice after poor Zepbound response. Wegovy is a different drug to discuss, including HD later for eligible adults. Its trial averages do not establish a success rate after tirzepatide failure. Review the treatment history and plan the next step with your prescriber.¹⁵

How long should I try Zepbound before deciding it doesn't work?

The OMA suggests considering another medicine below 5% loss after 12 to 16 weeks at the highest tolerated dose. This is a review point, not a required waiting period. On the fastest label schedule, 15 mg starts after 20 weeks; adding the review interval gives about 7 to 8 months from the first shot.⁴³

What percentage of people don't respond to Zepbound?

In SURMOUNT-1, the estimated share below 5% loss at 72 weeks was 9.1% in the 15 mg group. It includes people who stopped treatment and uses estimates for missing weights. It is not the percentage whose bodies cannot respond to tirzepatide.³

Is anything stronger than Zepbound?

There is no approved, proven stronger rescue specifically for Zepbound nonresponders. Wegovy HD has not been tested head to head against Zepbound. Retatrutide and CagriSema remain investigational; their trial results do not establish what would work after Zepbound failed.⁵¹⁷¹⁸

Will Wegovy work if Zepbound didn't?

It might. A 2026 case report described one man who lost 4.8% during tirzepatide treatment, then about 16% of his switch-day weight on semaglutide. One person's result cannot predict yours. The study reporting 2.9% versus 8.1% involved the opposite switch, so those are not success estimates for Wegovy after Zepbound.¹¹⁶

Can I switch straight from Zepbound 15 mg to Wegovy 2.4 mg?

Do not choose a Wegovy dose from your Zepbound dose. The labeled new-start schedule begins at 0.25 mg, and there is no approved conversion between the two drugs. Your prescriber decides how to switch. Do not take them together.⁵³

How long until I can get Wegovy HD after Zepbound?

On the standard new-start schedule, the earliest HD step is treatment week 21—after 20 completed weeks. That requires at least 4 weeks tolerating 2.4 mg and a need for more weight reduction. Your actual switch plan may take longer.⁵

Is Mounjaro different from Zepbound?

They have different approved uses but contain the same drug, tirzepatide. Changing the brand does not give you a different active drug or establish a solution to poor tirzepatide response.¹⁵³

Is a GLP-1 pill a good next step after Zepbound?

It can be worth discussing when injections, access or maintaining earlier weight loss are the issue. Pills are not proven to rescue Zepbound nonresponse. ATTAIN-MAINTAIN studied people who had already lost weight—not people Zepbound had failed.¹⁰

What if I couldn't handle Zepbound's side effects?

Ask about a lower maintenance dose, slower dose increases or a different treatment. Five mg is an approved long-term dose. Wegovy is not guaranteed to be gentler; more participants stopped semaglutide than tirzepatide for gastrointestinal side effects in SURMOUNT-5. Severe symptoms need medical care, not more waiting.³²

I lost weight on Zepbound and then stopped. Did it stop working?

Not necessarily. Keeping lost weight off can still be a treatment benefit. The plateau analysis used a specific definition—less than 5% change over 12 weeks and later intervals—not a date when everyone stops losing. Discuss the health goal still unmet and a maintenance plan.⁶

Can I take more than 15 mg of Zepbound?

Fifteen mg once weekly is the highest approved dose. Do not increase beyond your prescription. A container marked 20 mg may contain four 5 mg doses; it is not a 20 mg weekly injection. Ask the pharmacist to confirm the amount per dose when a label is unclear.³

Should I wait for retatrutide?

Do not stop available care just to wait for a company timetable. Lilly plans an FDA submission in the first quarter of 2027; that is not an approval date. Ask about care available now or a legitimate clinical trial—not a research-peptide seller.¹⁷¹²

Will insurance cover Wegovy after Zepbound?

It depends on the specific plan's benefits, drug list and authorization rules. Caremark's announced October 1, 2026 expansion is optional for plan sponsors, not automatic coverage for every member. Keep your starting weight and Zepbound history, and request the written rules for Wegovy.⁷

How much does it cost to switch from Zepbound to Wegovy without insurance?

Current NovoCare prices are $199 for up to two eligible starter fills, then $349 for doses through 2.4 mg; HD is $399. Our 13-fill examples total $4,237 or $4,637 for 364 days, before care fees and assuming unchanged prices and eligible offers. Without the starter offer, they are $4,537 or $4,937.⁸

What if no GLP-1 works for me?

See an obesity medicine doctor about non-GLP-1 medicines, a carefully reviewed combination or a surgery consult. Qsymia and Contrave have different risks and are not right for everyone. Surgery guidelines support assessment at BMI 35 or higher and for selected patients below that threshold.²⁶²⁷²⁵

Still not sure which GLP-1 program is right for you? Take our free matching quiz. It takes about 2 minutes. → Find My GLP-1 Path

Additional retatrutide filing source: Lilly’s July 23, 2026 announcement.

This page is for information only and isn't medical advice. A licensed clinician decides what's right for you.

Sources

1. La Vignera S, Condorelli RA. Tirzepatide nonresponse with subsequent semaglutide response in class 2 obesity. JCEM Case Reports, August 31, 2026. Read source.
2. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. NEJM, 2025. SURMOUNT-5. Read source.
3. Eli Lilly. Zepbound prescribing information, revised August 2026. Dose steps, maintenance doses, trial results, multidose presentations and safety. Read source.
4. Obesity Medicine Association. Top Weight Loss Medications, August 12, 2026. General 5% treatment-review guidance. Read source.
5. Novo Nordisk. Wegovy prescribing information, revised June 2026. Formulations, indications, STEP UP, OASIS 4, dose schedules and safety. Read source.
6. Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity, 2025. Read source.
7. CVS Health. Caremark expanded GLP-1 coverage options announcement, May 28, 2026. Effective-date and plan-sponsor conditions. Read source.
8. NovoCare Pharmacy. Wegovy self-pay prices and savings-offer terms. Checked September 22, 2026. Read source.
9. Eli Lilly. Foundayo prescribing information. Read source.
10. ATTAIN-MAINTAIN investigators. Orforglipron after injectable incretin treatment. Nature Medicine, May 12, 2026. Read source.
11. Ard J, et al. Weight reduction over time by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes, Obesity and Metabolism, 2025. Read source.
12. FDA. Concerns with unapproved GLP-1 drugs used for weight loss, including retatrutide and compounded products. Read source.
13. Ro. Weight-loss program pricing and advertised medication menu. Checked September 22, 2026. Read source.
14. LillyDirect. Zepbound self-pay prices and Journey offer terms. Checked September 22, 2026. Read source.
15. Eli Lilly. Mounjaro prescribing information and August 28, 2026 cardiovascular-indication announcement. Prescribing information · Approval announcement.
16. Weill Cornell Medicine. Real-world weight-loss outcomes in weight-reduced patients treated with tirzepatide. Obesity, 2026; PMID 41902614. Read source.
17. Eli Lilly. TRIUMPH-1 results, May 21, 2026; additional trials and planned first-quarter 2027 submission, July 23, 2026. Company announcements. Read source.
18. Novo Nordisk. REDEFINE 4 results and submission status, February 23, 2026. Company-issued announcement. Read source.
19. FDA. Policies for compounders as national GLP-1 supply begins to stabilize; tirzepatide and semaglutide shortage determinations. Read source.
20. Eli Lilly. SURMOUNT-MAINTAIN results, May 12, 2026. Company report of the maintenance trial. Read source.
21. CMS. Medicare GLP-1 Bridge program dates, operation and covered products. Checked September 22, 2026. Read source.
22. Sesame. Online weight-loss program pricing, clinician choice and controlled-medication restrictions. Checked September 22, 2026. Read source.
23. Medicare.gov. Weight-loss drugs: Bridge eligibility, cost and ordinary Part D indication rules. Checked September 22, 2026. Read source.
24. Ro. GLP-1 insurance coverage tool, covered services and government-plan restrictions. Checked September 22, 2026. Read source.
25. ASMBS/IFSO. Indications for Metabolic and Bariatric Surgery, 2022. Read source.
26. Qsymia prescribing information. Adult trial results, pregnancy contraindication and safety. Read source.
27. Currax. Contrave prescribing information, revised November 2025. COR-I results, contraindications and boxed warning. Read source.
28. Public r/Zepbound discussion, “Weight loss slowing down for a super responder.” Used only for reader language, not medical evidence. Read source.
29. Ro. Terms of Use, subscription renewal, cancellation and refund provisions. Checked September 22, 2026. Read source.
30. Diane and David Socorro. Public Trustpilot reviews of Ro, with experience dates of September 6 and September 9, 2026. Individual experiences, not medical evidence. Read source.